Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTLNASDAQ:EUDANASDAQ:FTRENASDAQ:INNV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$18.52-2.1%$18.24$15.45▼$35.84$545.98M1.03419,770 shs312,825 shsEUDAEUDA Health$3.72-0.3%$3.73$2.71▼$6.30$138.58M-0.0383,990 shs100,957 shsFTREFortrea$5.32-2.4%$5.22$3.97▼$28.41$493.23M1.591.89 million shs4.33 million shsINNVInnovAge$3.89+2.6%$3.57$2.60▼$6.69$511.70M0.5552,615 shs52,510 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%+0.48%+14.61%-7.85%-14.67%EUDAEUDA Health0.00%+10.36%-3.87%-8.13%+39.70%FTREFortrea0.00%-13.08%+16.20%-37.86%-76.65%INNVInnovAge0.00%+2.71%-10.61%+19.94%-10.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSTLCastle Biosciences2.4114 of 5 stars3.53.00.00.01.92.50.0EUDAEUDA HealthN/AN/AN/AN/AN/AN/AN/AN/AFTREFortrea3.8902 of 5 stars3.91.00.00.02.80.83.8INNVInnovAge1.2667 of 5 stars2.82.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 3.00Buy$37.0099.78% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/AFTREFortrea 1.86Reduce$15.00181.95% UpsideINNVInnovAge 1.50Reduce$5.0028.53% UpsideCurrent Analyst Ratings BreakdownLatest EUDA, CSTL, INNV, and FTRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.005/2/2025FTREFortreaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$7.004/10/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$12.00 ➝ $6.004/9/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$332.07M1.61$0.96 per share19.22$16.28 per share1.14EUDAEUDA Health$4.01M34.46N/AN/A($0.07) per share-53.14FTREFortrea$2.70B0.18$1.53 per share3.47$15.19 per share0.35INNVInnovAge$763.85M0.69N/AN/A$2.04 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)EUDAEUDA Health-$15.36MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)FTREFortrea-$328.50M-$8.79N/A4.160.37-29.43%2.84%1.06%8/11/2025 (Estimated)INNVInnovAge-$21.34M-$0.23N/A64.83N/A-3.75%-11.91%-5.85%N/ALatest EUDA, CSTL, INNV, and FTRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/6/2025Q3 2025INNVInnovAge-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AFTREFortreaN/AN/AN/AN/AN/AINNVInnovAgeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.029.379.19EUDAEUDA HealthN/A0.180.15FTREFortrea1.220.970.97INNVInnovAge0.040.780.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%EUDAEUDA Health4.35%FTREFortreaN/AINNVInnovAge12.26%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.50%EUDAEUDA HealthN/AFTREFortrea0.38%INNVInnovAge1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54028.87 million27.00 millionOptionableEUDAEUDA Health237.15 millionN/ANot OptionableFTREFortrea15,50090.50 million90.16 millionOptionableINNVInnovAge2,350135.01 million133.12 millionOptionableEUDA, CSTL, INNV, and FTRE HeadlinesRecent News About These CompaniesInnovAge (NASDAQ:INNV) Trading Down 4.6% - Here's WhyJune 9, 2025 | marketbeat.comInnovAge Holding Corp. (NASDAQ:INNV) Director Acquires $34,476.00 in StockMay 31, 2025 | marketbeat.comInnovAge Holding Corp. (NASDAQ:INNV) Director Richard C. Zoretic Acquires 14,265 SharesMay 31, 2025 | marketbeat.comInsider Buying: InnovAge Holding Corp. (NASDAQ:INNV) Director Buys 20,000 Shares of StockMay 31, 2025 | marketbeat.comInnovAge (NASDAQ:INNV) Trading 3.2% Higher - Time to Buy?May 31, 2025 | marketbeat.comInsider Buying: InnovAge Holding Corp. (NASDAQ:INNV) Director Buys 8,450 Shares of StockMay 31, 2025 | insidertrades.comInnovAge (NASDAQ:INNV) Shares Gap Down - Time to Sell?May 23, 2025 | marketbeat.comInsider Buying: InnovAge Holding Corp. (NASDAQ:INNV) COO Buys 10,000 Shares of StockMay 14, 2025 | insidertrades.comInnovAge Reports Mixed Earnings with Strong GrowthMay 12, 2025 | tipranks.comInnovAge Holding Corp. (INNV) Q3 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comInnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025May 6, 2025 | globenewswire.comInnovAge Holding Corp. to Announce Fiscal Q3 2025 Financial Results and Host Conference Call on May 6April 22, 2025 | quiverquant.comInnovAge to Announce Fiscal Third Quarter 2025 Financial Results and Host Conference Call Tuesday, May 6, 2025April 22, 2025 | globenewswire.comWall Street Set to Open Mixed Thursday as Investors Parse Key Employment, Manufacturing DataApril 17, 2025 | msn.comInnovAge Champions PACE at State Capitols to Protect Critical Care for SeniorsApril 17, 2025 | globenewswire.comInnovAge Announces Participation at the KeyBanc Capital Markets Healthcare ForumMarch 4, 2025 | globenewswire.comInnovAge Reports Mixed Sentiment in Latest Earnings CallFebruary 5, 2025 | tipranks.comInnovAge reaffirms FY2025 guidance with revenue projected between $815M and $865MFebruary 5, 2025 | msn.comInnovAge Holding Corp. (INNV) Q2 2025 Earnings Call TranscriptFebruary 5, 2025 | seekingalpha.comInnovAge Holding Corp. Reports Q2 2025 Financial ResultsFebruary 4, 2025 | tipranks.comInnovAge Holding Corp. Reports Q2 Fiscal 2025 Financial Results with Revenue Growth but Increased LossesFebruary 4, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEUDA, CSTL, INNV, and FTRE Company DescriptionsCastle Biosciences NASDAQ:CSTL$18.52 -0.39 (-2.06%) Closing price 04:00 PM EasternExtended Trading$18.55 +0.03 (+0.16%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.EUDA Health NASDAQ:EUDA$3.72 -0.01 (-0.27%) Closing price 03:59 PM EasternExtended Trading$3.74 +0.02 (+0.54%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.Fortrea NASDAQ:FTRE$5.32 -0.13 (-2.39%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.16 (+3.01%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.InnovAge NASDAQ:INNV$3.89 +0.10 (+2.64%) Closing price 04:00 PM EasternExtended Trading$4.03 +0.14 (+3.57%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
